Acrivon Therapeutics, Inc. - Common Stock (NQ:ACRV)

1.530 +0.060 (+4.08%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist

Price and Volume

Volume	503,640
Open	1.560
Bid (Size)	1.450 (1,200)
Ask (Size)	1.530 (3,100)
Prev. Close	1.470
Today's Range	1.460 - 1.580
52wk Range	1.050 - 3.560
Shares Outstanding	21,925,982
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

March 19, 2026

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

March 17, 2026

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Performance

YTD	-37.8%	-37.8%
1 Month	-4.4%	-4.4%
3 Month	-48.1%	-48.1%
6 Month	-18.6%	-18.6%
1 Year	+12.5%	+12.5%

More News

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

February 23, 2026

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

February 18, 2026

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Registration Momentum Builds Across the Oncology Pipeline

February 17, 2026

From USA News Group

Via GlobeNewswire

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

January 23, 2026

From Acrivon Therapeutics, Inc

Via GlobeNewswire

On Friday, there are stocks with unusual volume. Let's take a look. ↗

January 09, 2026

Via Chartmill

Here are the top movers in Thursday's session. ↗

January 08, 2026

Via Chartmill

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

January 08, 2026

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗

January 06, 2026

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

January 06, 2026

Via Chartmill

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

January 06, 2026

From Acrivon Therapeutics, Inc

Via GlobeNewswire

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

December 17, 2025

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates

December 17, 2025

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

November 13, 2025

From Acrivon Therapeutics, Inc

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

October 22, 2025

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 01, 2025

From Acrivon Therapeutics, Inc

Via GlobeNewswire

In today's session, these stocks are experiencing unusual volume. ↗

September 09, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 09, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 08, 2025

Via Benzinga

Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗

September 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 05, 2025

Via Benzinga

Frequently Asked Questions

Is Acrivon Therapeutics, Inc. - Common Stock publicly traded?

Yes, Acrivon Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Acrivon Therapeutics, Inc. - Common Stock trade on?

Acrivon Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Acrivon Therapeutics, Inc. - Common Stock?

The ticker symbol for Acrivon Therapeutics, Inc. - Common Stock is ACRV on the Nasdaq Stock Market

What is the current price of Acrivon Therapeutics, Inc. - Common Stock?

The current price of Acrivon Therapeutics, Inc. - Common Stock is 1.530

When was Acrivon Therapeutics, Inc. - Common Stock last traded?

The last trade of Acrivon Therapeutics, Inc. - Common Stock was at 04/08/26 04:00 PM ET

What is the market capitalization of Acrivon Therapeutics, Inc. - Common Stock?

The market capitalization of Acrivon Therapeutics, Inc. - Common Stock is 33.55M

How many shares of Acrivon Therapeutics, Inc. - Common Stock are outstanding?

Acrivon Therapeutics, Inc. - Common Stock has 34M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.